Journal of the American Academy of Dermatology · 2025
Patients with PSOriasis and Suppurative Hidradenitis (PSO-SH) share genetic risk factors and are at risk of increased morbidity.
СтатьяПоддержка NIH: внешняя программаНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wiala Antonia, Elhage Kareem G, Leung Andrea, Young Albert T, Gregory Mark, Adrianto Indra, Zhou Li, Mi Qing-Sheng, Kumar Sugandh, Orcales Faye, Yeroushalmi Samuel, Haran Kathryn, Liu Jared, Naik Haley B, Liao Wilson, Posch Christian
Аннотация
BACKGROUND: Select patients are diagnosed with both psoriasis (PSO) and hidradenitis suppurativa (HS), leading to a unique disease pattern. Genetic risk factors remain unidentified.
METHODS: The study harnessed an international collection of patients with PSO and HS (PSO-SH). Clinical and genetic data were collected and analyzed.
RESULTS: Eighty-seven PSO-SH patients (70% female) were identified. They had a high number of comorbidities (89%) and worse general physical health compared to PSO-only (OR: 3.09; 95% CI: 1.56-6.12) or HS-only (OR: 2.5; 95% CI: 1.23-5.00) patients. PSO-SH patients were at significantly higher risk of having Crohn's disease (OR: 4.6-11.9; 95% CI). Data revealed the highest overall genetic risk score for PSO-SH patients (PSO-polygenic risk score; 108.22), followed by PSO (101.18), HS (99.84), and healthy controls (98.58). High non-human leukocyte antigen scores were associated with an increased risk for developing both PSO and HS, indicating a distinct biological profile compared to HS-only and PSO-only individuals.
LIMITATIONS: Some clinical information was collected retrospectively.
CONCLUSIONS: This study highlights a shared genetic susceptibility of HS and PSO at non-human leukocyte antigen loci. Recognizing PSO-SH patients as a distinct patient group with high morbidity and increased risk for developing Crohn's disease will help to improve patient management.
METHODS: The study harnessed an international collection of patients with PSO and HS (PSO-SH). Clinical and genetic data were collected and analyzed.
RESULTS: Eighty-seven PSO-SH patients (70% female) were identified. They had a high number of comorbidities (89%) and worse general physical health compared to PSO-only (OR: 3.09; 95% CI: 1.56-6.12) or HS-only (OR: 2.5; 95% CI: 1.23-5.00) patients. PSO-SH patients were at significantly higher risk of having Crohn's disease (OR: 4.6-11.9; 95% CI). Data revealed the highest overall genetic risk score for PSO-SH patients (PSO-polygenic risk score; 108.22), followed by PSO (101.18), HS (99.84), and healthy controls (98.58). High non-human leukocyte antigen scores were associated with an increased risk for developing both PSO and HS, indicating a distinct biological profile compared to HS-only and PSO-only individuals.
LIMITATIONS: Some clinical information was collected retrospectively.
CONCLUSIONS: This study highlights a shared genetic susceptibility of HS and PSO at non-human leukocyte antigen loci. Recognizing PSO-SH patients as a distinct patient group with high morbidity and increased risk for developing Crohn's disease will help to improve patient management.